TOPIC

New medical drugs

New medical drugs
Latest news and updates on medical drug research and breakthroughs.
A worker checks the position of a feeding tray in a pharmaceutical manufacturing facility at the Hengrui Biomedical Industrial Park in Lianyungang in Jiangsu province, on December 13, 2021. Photo: Getty Images
China economy

Opinion | How China engineered the rapid rise of its drug innovation industry

A market once dominated by generics is now an AI-powered pharmaceutical hub drawing billion-dollar investments from the likes of Pfizer and GSK.

videocam
Hansoh Pharmaceutical

6 of the best: the billion-dollar biotechs putting China on the map

China’s private sector

Fosun brings UK particle therapy to mainland China in advanced cancer care push

Biomedicine: Companies

China biotech forum bills antibody cancer drugs as next-generation treatment

Biotech insiders tout antibody-drug conjugates as the next big thing in cancer treatment, with firms urged to pursue global strategies.

Antibody drug conjugates are targeted medicines that deliver chemotherapy agents to cancer cells. Photo: Shutterstock
Hong Kong stock market

China’s Akeso gets share boost as data shows cancer drug’s benefits

Lung-cancer drug ivonescimab is ‘potentially two to three years ahead of competitors’, analyst says.

Biomedicine: Companies

Hansoh and Leads Biolabs clinch US$2.5 billion in global drug licensing deals

Two mainland biotech firms win global attention as Roche and Dianthus sign major licensing pacts, highlighting China’s growing role in next-generation drug development.

Advertisement
Advertisement
Advertisement
Mergers & Acquisitions

CK Life unit merges with TransCode as Li Ka-shing firm eyes anticancer drugs

Upon completion of the transaction, CK Life will own about 9.1 per cent of TransCode’s outstanding common shares.

Company flags flutter outside Cheung Kong Centre. CK Life Sciences International is set to merge its subsidiary Polynoma with TransCode Therapeutics to boost its pipeline of anticancer drugs. Photo: Shutterstock
Health & Fitness

Li Ka-shing-backed focused ultrasound therapy treats 1 millionth case

The therapy, which uses ultrasound energy to treat a number of diseases including cancer, is gaining global traction, a US expert says.

United States

China’s pharmaceutical sector surges amid growth in sales, licensing income

Strong growth momentum and global push expected to continue, HSBC says.

Biomedicine: Industry Trends

China’s drug developers stretch to become a global force

Although a start-up’s recent triumph is seen as a ‘DeepSeek moment’, domestic players still trail world-beating pharma firms, experts say.

10
Illustration: Henry Wong
IPO

Chinese healthcare, biotech firms flock to Hong Kong for IPOs

September yields at least 23 listing applications from mainland biotech firms eyeing the city’s lucrative fundraising market.

The Hang Seng Biotech index, which tracks the 50 largest biotech, pharmaceutical and medical-device firms listed in Hong Kong, has surged 109 per cent this year. Photo: Shutterstock
Biomedicine: Companies

Pfizer’s Metsera acquisition to spur Chinese search for new weight drugs

The deal, worth up to US$7.3 billion, will encourage ongoing investment by mainland players but not draw in new rivals, analysts say.

Biomedicine: Companies

China’s Hengrui gets boost from fifth drug-licensing deal of year

Shares rise after Mumbai-based Glenmark Pharmaceuticals strikes deal for cancer drug.

US-China relations

Opinion | Why US-China health and drugs cooperation must top Trump-Xi agenda

The years-long impasse harms both nations and the world, and the stakes in global health security could not be higher.

videocam
Illustration: Craig Stephens
Health in China

Beijing tackles drug price wars with new tendering rules in anti-involution push

China’s new drug procurement rules prioritise quality over price in a bid to curb cutthroat competition.

Employees work on the production line of Shijiazhuang No 4 Pharmaceutical in Shijiazhuang, Hebei province. Photo: VCG/VCG via Getty Images
Biomedicine: Companies

Ascletis trial shows drug candidate ASC47 boosts semaglutide weight loss effect

Chinese biotech firm is among dozens of mainland drug makers seeking to compete in the global market for diabetes and weight-loss drugs.

Fosun Group

Fosun’s Henlius in talks with Johnson & Johnson, Roche on cancer drug

Shanghai Henlius Biotech is in talks with multinational pharmaceutical firms about selling them the rights to an experimental cancer drug.

Advertisement
Advertisement
Advertisement
China technology

China’s biotech industry is gaining on the US. Can tariffs hold them back?

Pharmaceutical firms in China have grown fast, but geopolitics and a long head start could keep US-based leaders at industry apex - for now.

videocam
Illustration: Lau Ka-kuen
China Future Tech briefing

Biomedicine | China goes big on weight-loss drugs in Novo, Eli Lilly challenge

Demand for anti-obesity drugs has expanded along with people’s waistlines, and Chinese companies are seeking to cash in with new treatments.

videocam
Biomedicine: Companies

Chinese pharma firms Hengrui, Hansoh expected to post strong first-half profits

Novel drug roll-outs and revenue from licensing buoy results.

Biomedicine: Companies

China’s biomedicine sector takes off

China’s novel drug industry is experiencing a meteoric rise, fuelled by the increased development of new medicines and the prospect of many patents expiring.

China to cash in on biomedicines ‘patent cliff’
Biomedicine: Companies

Chinese drug developer XTalPi surges on US$6 billion deal

Deal with DoveTree, established by Harvard professor Gregory Verdine, adds to growing list of licensing tie-ups with Chinese firms.

XTalPi will use its AI-driven drug discovery platform to discover and develop drug candidates for cancer, immune and inflammatory diseases, neurological disorders and metabolic dysregulation, the companies said. Illustration: Shutterstock
Biomedicine: Companies

Chinese drug start-ups poised for 2025 profits, in industry milestone

Innovent likely to post a first-half net profit of US$36.4 million, and BeOne’s first-half net profit is expected to come in at US$42 million.

Banking & finance

Wuxi AppTec joins funding rush as appetite grows for China’s biotech

WuxiAppTec raised HK$7.70 billion (US$981 million) in a sale of additional shares to fund its global expansion.

Biomedicine: Companies

GSK to pay Hengrui US$12.5 billion for global rights to 12 drug projects

The deal would give GSK the rights to develop the drug for HRS-9821 and 11 preclinical programmes owned by Jiangsu Hengrui Pharmaceuticals.

4
The research lab at the Hengrui Biomedical Industrial Park in Lianyungang in eastern China’s Jiangsu province on December 13, 2021. Photo: Getty Images.
Biomedicine: Companies

Pfizer, Chinese biotech firm 3SBio complete licensing deal for cancer drug

Pfizer agreed to an upfront payment of US$1.25 billion, US$150 million for mainland rights and a US$100 million equity investment in 3SBio.

Pfizer agreed to buy a 1.3 per cent equity stake in 3SBio for HK$785 million. Photo: Shutterstock
Biomedicine: Companies

Hong Kong firms eye Chinese medicine opportunities on the mainland: HKTDC

Hong Kong Trade Development Council says streamlined procedures opened a more convenient channel for companies to expand into the mainland.

China manufacturing

China approving innovative drugs at record pace, shifting momentum from West

‘If we’re not careful, every drug could be made in China,’ warned former head of US Food and Drug Administration in May.

videocam
8
Advertisement
Advertisement
Advertisement
Help preserve 120 years of quality journalism.
SUPPORT NOW
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement